The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they ...

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...